Use of new biomarker for selecting and determining response to exercise regimen

Exercise improves metabolic health and prevents the complications of obesity and type 2 diabetes. The inventors hypothesized that skeletal muscle contraction produces a cellular stress signal triggering adipose tissue lipolysis to sustain fuel availability during exercise. They aimed at identifying novel exercise-regulated exerkines, able to promote lipolysis. Growth and Differentiation Factor 15 (GDF15) gene expression and secretion increased rapidly upon skeletal muscle contraction. GDF15 protein was up-regulated in conditioned media from both acute and chronic exercise-stimulated myotubes. The inventors further show that physiological concentrations of recombinant GDF15 protein increase lipolysis in human adipose tissue. The inventors herein provide the first evidence that GDF15 is a novel exerkine produced by skeletal muscle contraction and able to target human adipose tissue to promote lipolysis. GDF15 could thus be suitable as a marker of exercise management.

Keywords: ELISA, RT-PCR, Immunoassay, Transcriptomics, Treatment Response in Metabolism, Cardiovascular, obesityrnPhysical activity
Patent Application number: European Procedure (Patents) (EPA) - 29 Juil. 2019 - 19 305 985.4
Inventors:
MORO CédricLAURENS Claire

Reference:

BIO19224-D1

    Business Developper
    contact
    Inserm Transfert
    Business Developer
    Patent filling date: 29-07-2019
    Rare disease: No
    Second indication: No

    You might also be interested in